Upstream Bio (UPB)
Developing verekitug, a TSLP-receptor antibody for severe respiratory diseases.
Something off on this page? Send us feedback.
Develops verekitug, a clinical-stage antibody for severe respiratory and inflammatory diseases, with severe asthma, nasal polyps, and COPD as current programs. It is a single-asset, pre-commercial sponsor whose revenue currently comes from reimbursed Japanese R&D work.
Develops verekitug, a fully human monoclonal antibody that blocks the thymic stromal lymphopoietin receptor. The program targets severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease, with clinical development designed around extended dosing intervals.
Operates as a clinical-stage, single-asset biopharmaceutical sponsor. Research and development is concentrated in-house while international trials, active ingredient production, and finished drug manufacturing are outsourced. Current revenue comes from reimbursed Japanese research and development work; there is no approved product or product-sales revenue.
Retains global research and development responsibility while Maruho holds Japanese development and commercialization rights. Progress depends on clinical and regulatory execution, third-party trial and manufacturing partners, and the sole candidate's ability to compete in already treated respiratory markets.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 11, 2026 | Truist Financial | Target | Target: — | Target: $25 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $261.3M · Total debt $954.0K · Total assets $281.2M · Shareholders' equity $271.0M
- Revenue
- $773.0K
- Operating income
- −$42.4M
- Net income
- −$39.7M
No dividends on record.
| Institutions | ≈ 92.52% | 50.68M shares | |
|---|---|---|---|
| 153 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.31% | 167.4K shares | |
| 5 holders · as of Sep 17, 2026 | |||
| Other | ≈ 7.17% | 3.93M shares | |
| remainder | |||
54.77M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
FMR LLCInstitution | 14.90% | 8.16M | as of Jun 30, 2026 |
Orbimed Advisors LLCInstitution | 10.40% | 5.69M | as of Jun 30, 2026 |
Norges BankInstitution | 6.88% | 3.77M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 6.85% | 3.75M | as of Jun 30, 2026 |
Decheng Capital LLCInstitution | 4.98% | 2.72M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 16, 2026 | Adam Houghton | officer: Chief Business Officer | −700 | $5.49 |
| Sep 16, 2026 | Everett Rand Sutherland | director, officer: Chief Executive Officer | −2,095 | $5.49 |
| Sep 16, 2026 | Aaron Deykin | officer: Chief Medical Officer | −895 | $5.49 |
| Sep 16, 2026 | Allison Ambrose | officer: General Counsel | −485 | $5.49 |
| Sep 16, 2026 | Michael Gray | officer: CFO and COO | −853 | $5.49 |
- AstraZeneca (ADR)
TSLP-pathway and eosinophil biologics across all three respiratory arenas.
- Sanofi (ADR)
Dupixent spans asthma, nasal polyps, and eosinophilic COPD.
- GSK (ADR)
Nucala and Exdensur span severe asthma, nasal polyps, and COPD.
- Amgen
Co-developed TSLP biologic Tezspire is the closest mechanism rival.
- Regeneron
Dupixent reaches all three target respiratory indications.
- Novartis (ADR)
Xolair contests severe asthma and chronic rhinosinusitis with nasal polyps.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Upstream Bio | $5.02 | −8.62% | $298.8M | — | — | 94.6 | −17.5% |
| AstraZeneca (ADR) | $163.70 | −2.77% | $261.12B | 25.3 | 15.4 | 4.3 | +6.4% |
| Sanofi (ADR) | $41.49 | −2.40% | $102.08B | 76.0 | — | 1.8 | +11.2% |
| GSK (ADR) | $49.82 | −1.77% | $101.62B | 16.1 | 9.2 | 2.3 | +5.3% |
| Amgen | $406.64 | −0.88% | $221.41B | 25.5 | 17.3 | 5.8 | +9.7% |
| Regeneron | $793.40 | −1.31% | $82.82B | 19.9 | 13.1 | 5.3 | +16.7% |
| Novartis (ADR) | $142.68 | +0.99% | $268.53B | 21.3 | 15.2 | 4.8 | +0.9% |
| Median | 23.3 | 15.2 | 4.5 | +8.0% |